Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT. To register for the Akebia virtual R&D Day, click here. The event will feature scientific experts James A. Tumlin, MD (NephroNet), V. Michael Holers, MD (University of Colorado Anschutz) and Jonathan Barratt, MD, PhD, ...